|
Alan Breier, M.D., was named vice president for medical and chief medical officer for Lilly in August 2003. He is a member of the Lilly Research Laboratories policy committee and the company's senior management council. Previously, Breier was a Lilly clinical research fellow, Zyprexa� product team leader, and vice president of pharmaceutical products forLilly.
Breier received a bachelor of arts degree, summa cum laude, from the University of Toledo (Ohio) in 1975. He received a doctor of medicine degree in 1980 from the University of Cincinnati School of Medicine. He served as a resident in psychiatry from 1980 to 1984 at Yale University School of Medicine.
Prior to joining Lilly, Breier completed a three-year research fellowship at the National Institute of Mental Health (NIMH) Intramural Research Program (IRP) and then became chief of the outpatient research program at the Maryland Psychiatric Research Center and associate professor of psychiatry at the University of Maryland School of Medicine. In 1993, he was recruited as chief of the unit of pathophysiology and treatment at the NIMH IRP, and then promoted to chief of the section of clinical studies. At the NIMH, he established a research program investigating the causes of schizophrenia and development of new treatments for this illness.
Breier joined Lilly as Lilly research fellow for Lilly Research Laboratories, a division of Lilly, in March 1997, the same year he was appointed adjunct professor of psychiatry at Indiana University School of Medicine in Indianapolis. The next year he was named team leader of the Zyprexa product team at Lilly. In 2000, he became adjunct professor of psychiatry at the University of Maryland School of Medicine.
Breier is the recipient of many awards, including the A.E. Bennet Award from the Society of Biological Psychiatry; Yale�s Lustman Award, which he won three times; and the Joel Elkes International Award from the American College of Neuropsychopharmacology for outstanding contributions to psychopharmacology. He is on the editorial board of scientific journals and has an extensive publication record totaling more than 200 scientific articles. He is included in The Best Doctors in America. Breier is editor of the books: The New Pharmacotherapy of Schizophrenia, Olanzapine (Zyprexa): A Novel Antipsychotic, and Current Issues in the Psychopharmacology of Schizophrenia. | 